Leerink Partners Maintains Hold Rating on Amgen with $305 Price Target

Leerink Partners analyst David Risinger has maintained a Hold rating on Amgen with a price target of $305.00. Risinger has a 5-star analyst rating with an average return of 8.7% and a 53.96% success rate. The company's quarterly revenue reached $9.18 billion, with a net profit of $1.43 billion, compared to last year's $8.39 billion revenue and $746 million net profit. The analyst consensus is Moderate Buy with a price target consensus of $328.42, a 15.37% upside from current levels.

Amgen Inc. (NASDAQ:AMGN) faced a mixed reaction from analysts following the company's earnings report and a revision of its Q3 2025 earnings estimate by Leerink Partners. The biopharmaceutical giant's stock has seen a 5.1% decline, trading at $284.67, after reporting earnings of $6.02 per share for the last quarter, exceeding analysts' expectations.

Leerink Partners analyst David Risinger, known for his 5-star analyst rating and an average return of 8.7%, maintained a Hold rating on Amgen with a price target of $305.00. Risinger revised his Q3 2025 earnings estimate for Amgen down to $5.13 per share from his previous estimate of $5.40. The consensus estimate for Amgen's current full-year earnings is $20.62 per share, with a price target consensus of $328.42, indicating a 15.37% upside from current levels [1].

Despite the earnings beat, the stock has faced downward pressure due to recent market conditions and analyst ratings. Other analysts have issued varying opinions on Amgen's stock. Mizuho raised its price target to $280.00 and gave the stock a neutral rating, while Guggenheim set a neutral rating with a target price of $288.00. Erste Group Bank downgraded Amgen from a strong-buy rating to a hold rating, and Cantor Fitzgerald restated a neutral rating with a target price of $305.00 [2].

Amgen's quarterly revenue reached $9.18 billion, with a net profit of $1.43 billion, compared to last year's $8.39 billion revenue and $746 million net profit. The company's market capitalization stands at $153.07 billion, with a P/E ratio of 23.28, a P/E/G ratio of 2.60, and a beta of 0.49. Institutional investors hold 76.50% of the stock, with corporate insiders owning 0.76% [1].

While the stock has experienced recent volatility, the company's strong earnings performance and continued growth in revenue suggest potential upside. Investors should closely monitor Amgen's earnings reports and analyst revisions for further insights.

References:
[1] https://www.marketbeat.com/instant-alerts/amgen-nasdaqamgn-given-new-31000-price-target-at-citigroup-2025-08-06/
[2] https://www.marketbeat.com/instant-alerts/leerink-partnrs-predicts-amgens-q3-earnings-nasdaqamgn-2025-08-07/